Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation
Rhea-AI Summary
Intensity Therapeutics (Nasdaq: INTS) was named a Platinum winner in the 2026 Pinnacle Awards for Healthcare in the Innovator in Biotech Solutions category on April 15, 2026.
The recognition highlights Intensity's intratumoral injection platform and lead investigational candidate INT230-6, a non-covalent drug-conjugation therapy combining cisplatin, vinblastine sulfate, and a penetration enhancer to improve tumor drug dispersion and immune recognition.
Positive
- None.
Negative
- None.
News Market Reaction – INTS
On the day this news was published, INTS declined 1.12%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
INTS fell 1.83% as peers showed mixed moves: ERNA up 1.05%, while MBRX and SNSE declined 8.46% and 9.66%. Momentum data also shows KZIA up 14.53% and PHIO/ERNA down around 2.8%, indicating broader biotech volatility rather than a company‑specific reaction to this award.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 27 | Earnings and update | Positive | -5.8% | Year-end results with >$20M raised, $11.9M cash, and strong clinical data. |
| Mar 24 | Patent issuance | Positive | -4.8% | New U.S. patent expanded IP to four U.S. patents and broad coverage. |
| Mar 12 | Clinical trial update | Positive | -6.2% | INVINCIBLE‑4 data showed higher pCR and fewer severe AEs with INT230‑6. |
| Mar 06 | Nasdaq compliance | Positive | +3.0% | Regained compliance with Nasdaq minimum bid price after 10 days ≥$1.00. |
| Feb 13 | Reverse stock split | Negative | -32.6% | 1-for-25 reverse split to boost share price and address Nasdaq deficiency. |
Recent positive clinical, IP, and financial updates have often been followed by negative price reactions, with 3 divergences versus 2 aligned moves.
Over recent months, Intensity reported several milestones. A 1-for-25 reverse split on Feb 18, 2026 and subsequent Nasdaq compliance on Mar 6 stabilized listing status. Clinical updates from INVINCIBLE‑4 on Mar 12 and broader year‑end data on Mar 27 highlighted encouraging response rates and survival. IP strength was reinforced by a new U.S. patent on Mar 24. Despite generally positive news flow, multiple announcements coincided with share price declines, framing today’s recognition as part of a broader late‑stage oncology execution story.
Market Pulse Summary
This announcement highlights external recognition of Intensity’s intratumoral INT230‑6 platform, adding to earlier clinical and financial disclosures. Recent history includes a 1-for-25 reverse split, restored Nasdaq compliance, and encouraging Phase 2 and prior study results. At a share price of $5.36, well below the 49.9975 52‑week high, investors may watch for additional clinical milestones, partnering activity, and funding developments to contextualize the significance of this award within the broader late‑stage pipeline story.
Key Terms
intratumoral injection medical
cisplatin medical
vinblastine sulfate medical
diffusion and cell penetration enhancer medical
non-covalently conjugates medical
cytotoxic drugs medical
immunotherapy medical
AI-generated analysis. Not financial advice.
Company receives the Platinum Award for Innovator in Biotech Solutions Category
The Company was selected a Platinum award winner in the Innovator in Biotech Solutions Category. INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. The drug consists of two proven, potent anti-cancer agents, cisplatin and vinblastine sulfate, and a diffusion and cell penetration enhancer molecule ("SHAO") that non-covalently conjugates to the two payload drugs, facilitating the dispersion of potent cytotoxic drugs throughout tumors and allowing the active agents to diffuse into cancer cells. INT230-6 is being developed in combination with standard-of-care therapies to improve the durability of response across multiple solid tumor indications.
"The recognition from the Pinnacle Award is a testament to Intensity's commitment to changing the future of cancer care," said Intensity Therapeutics Co-Founder and CEO Lewis H. Bender. "INT230-6 represents a new, unique methodology for cancer cell death that holds the potential to shift the cancer treatment from a short-term death sentence to chronic diseases, even for malignancies that are unresponsive to immunotherapy."
The Pinnacle Awards is an esteemed annual awards program dedicated to recognizing and celebrating outstanding achievements across various industries. Its mission is to honor companies, products, and individuals that have demonstrated exceptional innovation, creativity, and impact in their fields. Each year, nominees are evaluated by industry experts, media professionals, and consultants who ensure that only the most deserving candidates receive recognition.
About Intensity Therapeutics
Intensity is a late-stage clinical biotechnology company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumor's dense, high-fat, pressurized environment following direct intratumoral injection. As a result of the saturation, Intensity's clinical trials have demonstrated the ability of INT230-6 to kill tumors and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases even for malignancies that do not respond to conventional immunotherapy. Intensity has completed two clinical studies that enrolled over 200 patients using INT230-6: a Phase 1/2 dose escalation study in metastatic cancers including sarcomas (NCT03058289), and a Phase 2 randomized control clinical trial in locally advanced breast cancer (the "INVINCIBLE-2 Study") (NCT04781725) in women without undergoing chemotherapy prior to their surgery. The Company initiated a Phase 3 trial in soft tissue sarcoma (the "INVINCIBLE-3 Study") (NCT06263231), testing INT230-6 as second or third-line monotherapy compared to the SOC with overall survival as an endpoint. Intensity also initiated a Phase 2 study in collaboration with The Swiss Group for Clinical Cancer Research, formerly SAKK, now the Swiss Cancer Institute (the "INVINCIBLE-4 Study") (NCT06358573) as part of a Phase 2/3 program evaluating INT230-6 followed by the SOC immunochemotherapy and the SOC alone for patients with presurgical triple-negative breast cancer. The pathological complete response rate is the endpoint. For more information about Intensity, including publications, papers, and posters about its novel approach to cancer therapeutics, visit www.intensitytherapeutics.com or review our SEC filings.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the Company's expected future plans, cash runway, development activities, projected milestones, business activities or results. When or if used in this communication, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the initiation, timing, progress and results of future preclinical studies and clinical trials and research and development programs; the need to raise additional funding before the Company can expect to generate any revenues from product sales; plans to develop and commercialize product candidates; the timing or likelihood of regulatory filings and approvals; the ability of the Company's research to generate and advance additional product candidates; the risk that product candidates that appear promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials; the implementation of the Company's business model, strategic plans for the Company's business, product candidates and technology; commercialization, marketing and manufacturing capabilities and strategy; the rate and degree of market acceptance and clinical utility of the Company's system; the Company's competitive position; the Company's intellectual property position; developments and projections relating to the Company's competitors and its industry; the Company's ability to maintain and establish collaborations or obtain additional funding; expectations related to the use of cash and cash equivalents and investments; our potential inability to satisfy the Nasdaq Capital Market's requirements for continued listing and be subject to delisting; estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other risks described in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and in the Company's subsequent SEC filings, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
Investor Relations Contact:
Justin Kulik
CORE IR
INTS@coreir.com
(516) 222-2560
Media Contact:
Matt Cossel
CORE IR
pr@coreir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/intensity-therapeutics-recognized-with-pinnacle-award-for-excellence-in-healthcare-innovation-302742689.html
SOURCE Intensity Therapeutics Inc.